

IND for X-linked retinoschisis gene therapy filed

Applied Genetic Technologies (Gainesville, Fla.) has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to conduct a phase 1 and 2 clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University of Florida, the company's XLRS product candidate uses "an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye", according to a press release.